News:

ADVOCACY UPDATE: NEW PMPRB REGULATIONS DELAYED UNTIL JULY 1, 2021

Our message was heard! On December 30, 2020 – just two days before the new PMPRB Guidelines were due to come into force – the Government of Canada advised stakeholders that implementation of the amended Patented Medicines Regulations has been further delayed until July 1, 2021, in order to focus attention on COVID-19. The Canadian Association of PNH Patients worked tirelessly in 2020 to ensure the new PMPRB guidelines would not impede PNH patients’ access to medicines and clinical trials. We are relieved the government took the right action to delay implementation. We are grateful to everyone who supported the #stopPMPRBnow campaign! In case you missed them, you can watch below some of the media interviews we did leading up to the decision to delay: CTV’s Your Morning Global News Montreal Montreal Gazette CTV News Calgary Danielle Smith Show 770 CHQR Radio Calgary (Start listening at 39:46) We will keep you posted as we…

Read more

A Year-End Update: #stopPMPRBnow campaign + Upcoming Projects

As we wrap up a year that has brought many unprecedented challenges to Canadians, and especially those already facing health challenges, we are also coming to the end of our hard-fought campaign against reforms to drug pricing in Canada. Thank you to so many within our PNH family and extended families for participating in the #stopPMPRBnow advocacy campaign. With your help, we’ve engaged with 172 federal and provincial government decision makers, federal representatives and party leaders more than 30,000 times through email, Facebook, Twitter and the news media. Without a doubt, our voices were heard! Here are some of the recent news stories featuring two brave PNH advocates: CTV’s Your Morning Global News Montreal Montreal Gazette CTV News Calgary Danielle Smith Show 770 CHQR Radio Calgary (Start listening at 39:46) We knew from the start that it would be an uphill battle against PMPRB reform to ensure that those living with PNH and other rare diseases…

Read more

NEWS RELEASE: Federal Government Must Delay Drug Pricing Reform to Safeguard Patient Lives During COVID-19

Today, the Canadian Association of PNH Patients, issued a news release pressing the Federal government to again delay the implementation of the new PMPRB Guidelines to focus its attention on the COVID-19 pandemic. “Now is not the time for PMPRB reform, especially when so many Canadians are still falling ill and dying from COVID-19,” said Barry Katsof, Founder and President, Canadian Association of PNH Patients. “We are now hearing that the availability of COVID-19 vaccines will be delayed in Canada due to a lack of manufacturing infrastructure in this country. Similarly, the new PMPRB Guidelines will limit access to important global healthcare innovations and clinical trials for all Canadians, including those living with rare diseases. We are imploring the government to focus on one issue at a time and get it right.” “The Liberal government must delay and revise the PMPRB rule changes. To try and fix known problems with…

Read more

Submission to Standing Committee on Health Study on PMPRB Reforms

On November 6, PNH Canada submitted a brief to the House of Commons Standing Committee on Health (HESA) to inform the study it is undertaking on the Final Guidelines issued by the Patented Medicine Prices Review Board (PMPRB) on October 23, 2020. Our submission included two powerful testimonials from Canadian PNH patients. We made our position clear – we are extremely concerned that the new guidelines will limit access to new and innovative treatments, clinical trials and other global innovations in medicine for Canadian patients living with PNH and other rare diseases. We also provided evidence on how these reforms are already having a quantifiable and detrimental, if not deadly, impact on our lives. PNH Canada has requested to appear before the HESA committee and looks forward to the opportunity to make our community’s voice heard on this important issue for all Canadians! Read our full submission here Click here…

Read more

Canadian Association of PNH Patients Launches #stopPMPRBnow Advocacy Campaign

On October 1, 2020, the Canadian Association of PNH Patients officially launched its #stopPMPRBnow advocacy campaign due to concerns regarding the proposed amendments to the Regulations governing the Patented Medicine Prices Review Board (PMPRB) set to come into effect on January 1, 2021 Those living with rare diseases – including PNH – cannot accept that lives continue to be put at risk by the uncertainty generated by the PMPRB reform process to date.  Join our #stopPMPRBnow campaign to urge the federal government to put a stop to the proposed PMPRB reform until we can be certain that the lives of Canadians won’t be put at further and unnecessary risk. To find out how you can get involved and make your voice heard to #stopPMPRBnow, contact us at advocacy@pnhca.org or click here to take action!  

Read more

REGISTER TODAY: #stopPMPRBnow Campaign – How You Can Help Protect PNH Lives

The PNH community is extremely concerned about the proposed amendments to the Regulations governing the Patented Medicine Prices Review Board (PMPRB), set to come into effect on January 1, 2021. We know that PMPRB reform is already having a quantifiable, detrimental, if not deadly, impact on Canadian PNH patients by limiting access to an approved treatment option, clinical trials and global innovations in PNH therapies – all of which are helping to improve, extend and save the lives of PNH patients in other countries. We cannot accept that our lives are being put at risk by the uncertainty generated by the PMPRB reform process. Find out how you can help protect the lives of Canadians living with PNH and other rare diseases! On September 30, 2020 at 12:00 p.m. EDT, please join the Canadian Association of PNH Patients and our presenters, Barry Katsof, Founder & President, Canadian Association of PNH…

Read more

REGISTER TODAY: 📢 PNH ADVOCACY WEBINAR – Sept. 10 @ 12:00PM EDT

REGISTER TODAY: Why drug pricing reform in Canada must be stopped to protect PNH patients New federal regulations governing the Patented Medicine Prices Review Board (PMPRB) and the regulation of drug prices in Canada will come into effect on January 1, 2021. On August 4, 2020, the Canadian Association of PNH Patients made a submission in response to the consultation currently underway regarding proposed amendments to the Regulations governing the PMPRB. Despite the most recent changes, as reflected in the June 2020 Draft Guidelines, we remain concerned that the health of Canadians living with PNH continues to be put at risk by the uncertainty generated by the PMPRB reform process to date. On September 10, 2020 at 12:00 p.m. EDT, please join the Canadian Association of PNH Patients and our presenters, Barry Katsof, Founder & President, Canadian Association of PNH Patients and Joanne Koskie, Managing Director, Advocacy Solutions for a free…

Read more

PMPRB Reform Already Having a Detrimental, If Not Deadly, Impact on Patients’ Lives

On August 4, the Canadian Association of PNH Patients made a submission in response to the consultation currently underway regarding proposed amendments to the Regulations governing the Patented Medicine Prices Review Board (PMPRB). Despite the most recent changes, as reflected in the June 2020 Draft Guidelines, we remain concerned that the health of Canadians living with PNH continues to be put at risk by the uncertainty generated by the PMPRB reform process to date.

Read more

Alexion Steps Up to Help Keep PNH Patients Safe

Patients who are part of the OneSource program and rely on public transit can now take a reimbursed ridesharing/taxi service to and from the infusion clinic where they receive their eculizumab treatments. Alexion Canada (the manufacturer of eculizumab) hopes this service will help alleviate any concerns patients may have regarding taking public transit when travelling to and from infusion clinics during this unprecedented time. Details about this program: The OneSource program is now offering travel assistance should a patient indicate that they regularly take public transit to and from their infusion clinic appointments. Patients will choose and book their own car service to and from their appointments. Alexion recommends using Uber, Talixo or Lyft as these companies have implemented strict policies around car cleaning in light of COVID-19. Lyft (Only available to residents in ON and BC) Website: https://www.lyft.com/rider How to use this service: https://help.lyft.com/hc/en-ca/articles/115013079988-How-to-request-a-ride Uber Website: https://www.uber.com/ca/en/ How to…

Read more

New Clinical Trial!

BioCryst Pharmaceuticals is recruiting for a first-in-human study of its novel oral therapy for PNH! BCX9930 is a novel, oral Factor D inhibitor currently in Phase 1 clinical development for the treatment of complement-mediated diseases, including PNH. This three-part study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCX9930 with single and multiple ascending doses. BioCryst Pharmaceuticals is currently recruiting both healthy subjects and those with PNH to enroll in the 148-participant study. Clinical trial sites for this study are currently located in South Africa. For more information on this clinical trial, visit ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04330534… For more information about BioCryst Pharmaceuticals’ Complement Program visit: https://www.biocryst.com/our-program/complement-program/

Read more